Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer

Clinical Cancer Research

Volumn 5, Issue 8, 1999, Pages 2069-2076

  Kenny, Frances S ^a   Hui, Rina ^c   Musgrove, Elizabeth A ^c   Gee, Julia M W ^b   Blamey, Roger W ^a   Nicholson, Robert I ^b   Sutherland, Robert L ^c   Robertson, John F R ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR; MESSENGER RNA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE MARKER; HUMAN; METASTASIS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYCLIN D1; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RNA, MESSENGER; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0032771839     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. 1 cyclins. Cell, 73: 1059-1065, 1993.
2. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
3. Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., and Weinberg, R. A. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell, 82: 621-630, 1995.
4. Fantl, V., Stamp, G., Andrews, A., Rosewell, I., and Dickson, C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev., 9: 2364-2372, 1995.
5. Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., and Schmidt, E. V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (Lond.), 369: 669-671, 1994.
6. 1 phase in rodent fibroblasts. Genes Dev., 7: 1559-1571, 1993.
7. 1 to complete the cell cycle. Proc. Natl. Acad. Sci. USA, 91: 8022-8026, 1994.
8. Weinstat-Saslow, D., Merino, M. J., Manrow, R. E., Lawrence, J. A., Bluth, R. F., Wittenbel, K. D., Simpson, J. F., Page, D. I., and Steeg, P. S. Overexpression of cyclin D1 mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat. Med., 1: 1257-1260, 1995.
9. Alle, K. M., Henshall, S. M., Field, A. S., and Sutherland, R. L. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin. Cancer Res., 4: 847-854, 1998.
10. Fantl, V., Smith, R., Brookes, S., Dickson, C., and Peters, G. Chromosome 11q13 abnormalities in human breast cancer. Cancer Surv., 18: 77-94, 1993.
11. Peters, G., Fantl, V., Smith, R., Brookes, S., and Dickson, C. Chromosome 11q13 markers and D-type cyclins in breast cancer. Breast Cancer Res. Treat., 33: 125-135, 1995.
12. Schuuring, E., Verhoeven, E., van Tinteren, H., Peterse, J. L., Nunnink, B., Thunnissen, F. B., Devilee, P., Cornelisse, C. J., van de Vijver, M. J., Mooi, W. J., and Michalides, R. J. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res., 52: 5229-5234, 1992.
13. Hui, R., Campbell, D. H., Lee, C. S. L., McCaul, K., Horsfall, D. J., Musgrove, E. A., Daly, R. J., Seshadri, R., and Sutherland, R. L. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene, 15: 1617-1623, 1997.
14. Schuuring, E. The involvement of the chromosome 11q13 region in human malignancies. Cyclin D1 and EMS1 are two new candidate oncogenes: a review. Gene (Amst.), 159: 83-96, 1995.
15. Berns, E., Foekens, J., van Staveren, I., van Putten, W., de Koning, H., Portengen, H., and Klijn, J. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene (Amst.), 159: 11-18, 1995.
16. Seshadri, R., Lee, C. S. L., Hui, R., McCaul, K., Horsfall, D. J., and Sutherland, R. L. Cyclin D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin. Cancer Res., 2: 1177-1184, 1996.
17. Buckley, M. F., Sweeney, K. J., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., deFazio, A., Watts, C. K., Musgrove, E. A., and Sutherland, R. L. Expression and amplification of cyclin genes in human breast cancer. Oncogene, 8: 2127-2133, 1993.
18. Gillett, C., Fantl, V., Smith, R., Fisher, C., Bartek, J., Dickson, C., Barnes, D., and Peters, G. Amplification and Overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res., 54: 1812-1817, 1994.
19. Bartkova, J., Lukas, J., Muller, H., Lutzhoft, D., Strauss, M., and Bartek, J. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer, 57: 353-361, 1994.
20. Bartkova, J., Lukas, J., Strauss, M., and Bartek, J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene, 10: 775-778, 1995.
21. Gillett, C., Smith, P., Gregory, W., Richards, M., Millis, R., Peters, G., and Barnes, D. Cyclin D1 and prognosis in human breast cancer. Int. J. Cancer, 69: 92-99, 1996.
22. Pelosio, P., Barbareschi, M., Bonoldi, E., Marchetti, A., Verderio, P., Caffo, O., Bevilacqua, P., Boracchi, P., Buttitta, F., Barbazza, R., Dalla Palma, P., and Gasparini, G. Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann. Oncol., 7: 695-703, 1996.
23. McIntosh, G. G., Anderson, J. J., Milton, I., Steward, M., Parr, A. H., Thomas, M. D., Henry, J. A., Angus, B., Lennard, T. W., and Horne, C. H. Determination of the prognostic value of cyclin D1 Overexpression in breast cancer. Oncogene, 11: 885-891, 1995.
24. Michalides, R., Hageman, P., Vantinteren, H., Houben, L., Wientjens, E., Klompmaker, R., and Peterse, J. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br. J. Cancer, 73: 728-734, 1996.
25. van Diest, P. J., Michalides, R. J., Jannink, L., van der Valk, P., Peterse, H. L., de Jong, J. S., Meijer, C. J., and Baak, J. P. Cyclin D1 expression in invasive breast cancer: correlations and prognostic value. Am. J. Pathol., 150: 705-711, 1997.
26. Borg, A., Sigurdsson, H., Clark, G. M., Ferno, M., Fuqua, S. A., Olsson, H., Killander, D., and McGurie, W. L. Association of INT2/ HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br. J. Cancer, 63: 136-142, 1991.
27. Hui, R., Cornish, A. L., McClelland, R. A., Robertson, J. F. R., Blamey, R. W., Musgrove, E. A., Nicholson, R. I., and Sutherland, R. L. Cyclin D1 and estrogen receptor mRNA expression are positively correlated in primary breast cancer. Clin. Cancer Res., 2: 923-928, 1996.
28. Foster, J. S., and Wimalasena, J. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol. Endocrinol., 10: 488-498, 1996.
29. 1-arrested human breast cancer cells. Oncogene, 12: 2315-2324, 1996.
30. Planas-Silva, M. D., and Weinberg, R. A. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell. Biol., 17: 4059-4069, 1997.
31. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-cdk2. J. Biol. Chem., 272: 10882-10894, 1997.
32. Musgrove, E. A., Hamilton, J. A., Lee, C. S., Sweeney, K. J., Watts, C. K., and Sutherland, R. L. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell. Biol., 13: 3577-3587, 1993.
33. Watts, C. K. W., Brady, A., Sarcevic, B., deFazio, A., Musgrove, E. A., and Sutherland, R. L. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol. Endocrinol., 9: 1804-1813, 1995.
34. Wilcken, N. R. C., Prall, O. W. J., Musgrove, E. A., and Sutherland, R. L. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin. Cancer Res., 3: 849-854, 1997.
35. Galea, M. H., Blamey, R. W., Elston, C. E., and Ellis, I. O. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res. Treat., 22: 207-219, 1992.
36. Hui, R., Ball, J. R., MacMillan, R. D., Prall, O. W. J., Campbell, D. H., Cornish, A. L., McClelland, R. A., Daly, R. J., Forbes, J. F., Blamey, R. W., Musgrove, E. A., Robertson, J. F. R., Nicholson, R. I., and Sutherland, R. L. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene, 16: 1053-1059, 1998.
37. Walker, K. J., Bouzubar, N., Robertson, J. F. R., Ellis, I. O., Elston, C. W., Blamey, R. W., Wilson, D. W., Griffiths, K., and Nicholson, R. I. Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res., 48: 6517-6522, 1988.
38. Lee, E. T. Statistical Methods for Survival Data Analysis. New York: John Wiley and Sons, 1992.
39. Muise-Helmericks, R. C., Grimes, H. L., Bellacosa, A., Malstrom, S. E., Tsichlis, P. N., and Rosen, N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J. Biol. Chem., 273: 29864-29872, 1998.
40. Russell, A., Thompson, A., Hendley, J., Trute, L., Armes, J., and Germain, D. Coordinated accumulation of cyclin D1 and D3 in breast cancer due to a novel post-transcriptional defect. Oncogene, 18: 1983-1991, 1999.
41. 1 cyclin expression in breast cancer cells. Oncogene, 16: 2865-2878, 1998.
42. Zwijsen, R. M. L., Wientjens, E., Klompmaker, R., van der Sman, J., Bernards, R., and Michalides, R. J. A. M. Cdk-independent activation of estrogen receptor by cyclin D1. Cell, 88: 405-415, 1997.
43. Neuman, E., Ladha, M. H., Lin, N., Upton, T. M., Miller, S. J., DiRenzo, J., Pestell, R. G., Hinds, P. W., Dowdy, S. F., Brown, M., and Ewen, M. E. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol. Cell. Biol., 17: 5338-5347, 1997.
44. kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.
45. kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
46. Pacilio, C., Germano, D., Addeo, R., Altucci, L., Petrizzi, V. B., Cancemi, M., Cicatiello, L., Salzano, S., Lallemand, F., Michalides, R., Bresciani, F., and Weisz, A. Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens. Cancer Res., 58: 871-876, 1998.